Gregory Kaufman

Final results of a multi-center phase 2 trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM)

Sheeba K. Thomas, Elisabet E. Manasanch, Sundar Jagannath, Neha Korde et autres

Abstract Background: In analyses conducted by the Spanish Myeloma Group, Mayo Clinic and International Myeloma Working Group, patients with HRSMM have a median time to progression to symptomatic disease of <2 years. Randomized trials of lenalidomide (LEN) +/- dexamethasone vs. observation (E3A06, …

us (code pays fourni par la source)

BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma

Hector Garcia Pleitez, Oren Pasvolsky, Lei Feng, Mahmoud Gaballa et autres

Abstract Introduction: B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory multiple myeloma (RRMM) have shown deep and durable responses. However, real-world data on early CAR T-cell expansion dynamics and its association with treatment-related toxicities remain incomplete. This study …

us (code pays fourni par la source)

P-321 Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation

Yosra Aljawai, Oren Pasvolsky, Krina K. Patel, Qaiser Bashir et autres

P-017 Impact of Genetic Ancestry on Outcomes and Toxicity of Ide-cel in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Christen Dillard, Michelle A.T. Hildebrandt, Hans C. Lee, Nilesh Kalariya et autres

OA-43 Interim Results of a Phase 2 Trial of Isatuximab-Lenalidomide for Patients with High-Risk Smoldering Multiple Myeloma

Sheeba K. Thomas, Elisabet E. Manasanch, Neha Korde, Hans C. Lee et autres

Management and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy

Penny Fang, Chelsea C. Pinnix, Susan Wu, Hans C. Lee et autres

us (code pays fourni par la source)

P1125: DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)

Javier Muñoz, Frederick L. Locke, Lazaros J. Lekakis, Herbert Eradat et autres

Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Despite recent progress in treating LBCL, approximately 50% to 60% of pts will either not achieve a complete response (CR) or will relapse with current first- or second-line treatments and require additional therapy. With …

us (code pays fourni par la source)

Efficacy of single-dose oral secnidazole for the treatment of trichomoniasis in women co-infected with trichomoniasis and bacterial vaginosis: a post hoc subgroup analysis of phase 3 clinical trial data

Christina A. Muzny, Olivia T. Van Gerwen, Gregory Kaufman, Steven Chavoustie

OBJECTIVES: Bacterial vaginosis (BV) and trichomoniasis are the most common causes of vaginitis. Both infections are associated with increased risk of acquisition and transmission of HIV and other sexually transmitted infections as well as adverse reproductive health outcomes. Co-infection is common, with …

us, in (code pays fourni par la source)

P1303: DARATUMUMAB-BASED MAINTENANCE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AFTER SALVAGE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

Oren Pasvolsky, Krina K. Patel, Qaiser Bashir, Mikael Rauf et autres

Topic: 22. Stem cell transplantation - Clinical Background: Maintenance therapy is considered standard of care after upfront autologous hematopoietic stem cell transplantation (auto-HCT) for patients with newly diagnosed multiple myeloma (MM). However, there is paucity of data on the use of maintenance …

us (code pays fourni par la source)

Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).

Frederick L. Locke, Lazaros J. Lekakis, Herbert Eradat, Javier Muñoz et autres

2517 Background: Approximately 50% to 60% of pts with r/r LBCL will either not achieve a complete response (CR) or will relapse with current treatments and require additional therapy. Autologous anti-CD19 chimeric antigen receptor T (CAR T) therapies have revolutionized the care …

us (code pays fourni par la source)

P-233: Retrospective, single-center, real-world experience of belantamab mafodotin in relapsed/refractory multiple myeloma

Melody Becnel, Christopher J. Ferreri, Lei Feng, Tiffany Richards et autres

Single-Dose Oral Secnidazole for Treatment of Trichomoniasis in Women With BV Co-infection [A119]

Christina A. Muzny, Gregory Kaufman, Anna Sematczyn, Brajesh Pandey et autres

INTRODUCTION: Bacterial vaginosis (BV) and trichomoniasis are the most common causes of vaginitis. Both infections are associated with increased risk for HIV/STIs and adverse reproductive health outcomes. Coexistence of BV pathogens and Trichomoniasis vaginalis is common, with co-infection rates of 60–80%. In …

us (code pays fourni par la source)